Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business
July 15, 2019
Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.
- Buyers
- Interpace Diagnostics Group, Inc., Ampersand Capital Partners
- Targets
- Biopharma Services business of Cancer Genetics, Inc.
- Sellers
- Cancer Genetics, Inc.
- Industry
- Healthcare Services
- Location
- New Jersey, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Pace Life Sciences Acquires Biopharma Global
September 8, 2022
Healthcare Services
Pace Life Sciences, a CDMO subsidiary of Pace, has acquired Biopharma Global, a Vienna, Virginia-based regulatory affairs consultancy that specializes in orphan and other high‑unmet‑need drug regulatory support. The acquisition expands Pace's regulatory strategy and submission capabilities for FDA and EMA filings, strengthening its end-to-end development and regulatory services for biotech and pharmaceutical clients.
-
Flagship Biosciences Acquires Interpace Pharma Solutions from Interpace Biosciences
September 1, 2022
Healthcare Services
Flagship Biosciences has acquired Interpace Pharma Solutions (IPS), a division of Interpace Biosciences, expanding Flagship's molecular pathology, cytogenetics, genomics and biomarker analytics capabilities. The deal follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies and adds a state-of-the-art laboratory in Research Triangle Park, North Carolina to Flagship's service offering.
-
1315 Capital and Ampersand Capital Partners Invest $20M in Interpace Biosciences
January 13, 2020
Healthcare Services
Interpace Biosciences entered into an agreement for a $20 million Series B Preferred Stock investment — $19 million from 1315 Capital and $1 million from existing investor Ampersand Capital Partners. The financing (and a coincident one-for-ten reverse stock split) is intended to help Interpace reach cash-flow break-even, accelerate growth and pursue acquisitions; Ampersand also exchanged its Series A preferred for the new Series B shares.
-
OncoCyte Corporation Acquires Insight Genetics
January 10, 2020
Healthcare Services
OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.
-
Praesidian Capital Acquires Undisclosed Genetics Business
September 18, 2019
Healthcare Services
Praesidian Capital announced the acquisition of an integrated clinical and laboratory services company operating in genetic medicine, focused on prenatal and preconception testing and hereditary cancer risk assessments. The deal is Praesidian’s first as an independent sponsor and will serve as a platform for national expansion and future add-on acquisitions.
-
Ampersand Capital Partners Completes Growth Equity Investment in GenDx
May 8, 2019
Biotechnology
Ampersand Capital Partners completed a minority growth equity investment in Genome Diagnostics B.V. (GenDx), a Utrecht-based provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. The partnership will support GenDx's organic growth and M&A strategy; Ampersand's David Parker and Operating Partner Mike Evans joined GenDx's board.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.